-----Original Message-----
From: W & M Rose <FEARME@bigpond.com>
To: mol-cancer@lists.meds.com <mol-cancer@lists.meds.com>
Date: Saturday, 7 November 1998 22:52
Subject: Re: [MOL] PJ NEEDS INFORMATION
> G'day PJ,
>As far as I can see, it would appear that camptosar is cpt-11, is this what
>you found? See the following info.
>Love Mam
>
>98639652 (Reference 1 of 4) Flag for Printing Order a Photocopy
>
>Camptosar's active species, SN-38 is an MDR-1 substrate (Meeting abstract).
>von Palffy S, Mechetner E, Garcia R, Fruehauf JP
>
>Proc Annu Meet Am Assoc Cancer Res (1997) 38:A2652 1997 ISSN:
>0197-016X
>
>P-Glycoprotein
>Camptothecin
>Drug Resistance, Neoplasm
>Substrate Specificity
> Tumor Cells, Cultured
>Cancerlit Database
>MEETING ABSTRACT
>Drug Synergism
> Cyclosporine
>Human
>
>
> Abstract
>
> Camptosar has been approved for 2nd line therapy of colon cancer. Greater
>than 50% of colon cancer specimens have been found to overexpress MDR-1.
>MDR-1 may be a significant factor in colon cancer drug resistance. We
>therefore evaluated the impact of MDR-I expression on camptosar resistance.
>The MDR-1 positive MCF-7 40F cells were 12-fold more resistant to SN-38
than
>Top of Abstract
> their MDR-1 negative parent MCF-7 WT cell line. MCF-7 40F
>resistance to SN-38 was fully reversed by 3 ug/mL of cyclosporin A. The
>substrate specificity of Pgp for SN-38 was evaluated using the UIC2 Shift
>Assay, which demonstrated increased UIC2 antibody binding in the presence
of
>SN- 38. These data demonstrate that SN-38 resistance can be mediated by
the
>MDR-1 P-glycoprotein.
>
>
>
>Oncotech Inc.
>Irvine
>CA 92614
>and:
>
> The Food and Drug Administration requires a detailed understanding of the
>interactions of new agents with blood proteins prior to approval for use.
>These regulatory requirements are based upon the knowledge that it is the
>free drug fraction of an agent which has the potential to elicit biological
>activity. In order to directly monitor drug- protein interactions in
>plasma, a fluorescence spectroscopic method employing two-photon excitation
>(TPE) was implemented. Direct fluorescence
>Top of Abstract
> detection of SN-38 was achieved in plasma at sub- micromolar
>levels using two-photon excitation (2PE) at 790 nm. Both SN-38 as well as
>Camptosar were found to be amenable to study using two photon
methodologies.
>Anisotropy measurements are currently being evaluated as a means of
directly
>determining the free and bound drug levels of SN-38 in human plasma. TPE
>fluorescence methods may eventually allow for direct and rapid screening of
>protein binding parameters in individual patient samples
>
>
>-----Original Message-----
>From: PSerritell@aol.com <PSerritell@aol.com>
>To: mol-cancer@lists.meds.com <mol-cancer@lists.meds.com>
>Date: Friday, 6 November 1998 8:22
>Subject: [MOL] PJ NEEDS INFORMATION
>
>
>>Hi Gang:
>>Mom just called regarding her visit today with oncologist.
>>
>>1-The onc said no 5FU Chemo until the shingles are gone.
>>2-The onc said that since moms CEA went up to 15 that they will start her
>on
>>Campostar.
>>3-Mom gained 4 more pounds since being out of hospital. (8 total since
>>hospital)
>>
>>
>>Now my questions are
>>1-Has any had the shingles and still received their chemo
>>2-What is Campostar Chemo (website or info appreciated)
>>3-Can Mom go back to using 5FU after Campostar?
>>4-Is weight gain good?
>>
>>I though I knew a site where Campostar is but I can't seem to find it. My
>>search engine is so slow today.
>>I would appreciate your help.
>>Thanks everyone.
>>Love, Hugs, Kisses,
>>PJ
>>143
>>------------------------------------------------------------------------
>>This is an automatically-generated notice. If you'd like to be removed
>>from the mailing list, please visit the Medicine-On-Line Discussion Forum
>>at <http://www.meds.com/con_faq.html>, or send an email message to:
>>majordomo@lists.meds.com
>>with the subject line blank and the body of the message containing the
>line:
>>unsubscribe mol-cancer your-email-address
>>where the phrase your-email-address is replaced with your actual email
>>address.
>>------------------------------------------------------------------------
>
>------------------------------------------------------------------------
>This is an automatically-generated notice. If you'd like to be removed
>from the mailing list, please visit the Medicine-On-Line Discussion Forum
>at <http://www.meds.com/con_faq.html>, or send an email message to:
>majordomo@lists.meds.com
>with the subject line blank and the body of the message containing the
line:
>unsubscribe mol-cancer your-email-address
>where the phrase your-email-address is replaced with your actual email
>address.
>------------------------------------------------------------------------
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
